Silverarc Capital Management’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-370,000
Closed -$1.57M 78
2024
Q2
$1.57M Sell
370,000
-108,079
-23% -$1.05M 0.37% 53
2024
Q1
$7.04M Sell
478,079
-780,562
-62% -$11.8M 1.95% 18
2023
Q4
$12.1M Sell
1,258,641
-5,517
-0.4% -$38.1K 3.6% 6
2023
Q3
$5.89M Buy
1,264,158
+48,483
+4% +$241K 1.79% 22
2023
Q2
$6.5M Sell
1,215,675
-146,134
-11% -$901K 2.01% 16
2023
Q1
$9.76M Buy
1,361,809
+749,334
+122% +$4.51M 4.03% 2
2022
Q4
$4.11M Buy
612,475
+512,475
+512% +$2.81M 1.18% 35
2022
Q3
$346K Buy
+100,000
New +$383K 0.12% 70
2021
Q3
Sell
-176,915
Closed -$4.75M 96
2021
Q2
$4.75M Buy
+176,915
New +$5.18M 2.12% 13

Other funds holding MGNX

Silverarc Capital Management's MGNX Position: Q3 2024 in Review

Silverarc Capital Management sold out of MacroGenics (MGNX) in Q3 2024, closing a stake of 370,000 shares — an estimated $1.57M sold.

Silverarc Capital Management first reported a position in MGNX in Q2 2021 and held it in 9 quarters. The position peaked at $12.1M in Q4 2023. 124 funds tracked by Wall St. Rank hold MGNX as of Q3 2024.

  • Silverarc Capital Management reported no remaining MacroGenics position as of Q3 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 370,000 MacroGenics shares in Q3 2024, an estimated $1.57M.
  • Silverarc Capital Management first reported a position in MacroGenics in Q2 2021 and held it in 9 quarters.
  • Silverarc Capital Management's MacroGenics position peaked at $12.1M in Q4 2023.
  • 124 funds tracked by Wall St. Rank held MacroGenics as of Q3 2024.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.